Introduction
Teicoplanin is a complex of five closely related glycopeptide antibiotics produced by Actinoplanes teichomyceticus (Greenwood, 1988) with a structure and spectrum of activity closely related to that of vancomycin. It is recommended for the treatment of staphylococcal infections including those associated with central venous lines (CVL) and is frequently administered as a daily bolus injection following a loading dose. Most of the published studies (Charbonneau & Gerraud 1988; Chow el al., 1993) show a similar efficacy for teicoplanin in comparison with vancomycin for the treatment of line-associated infections with coagulase-negative staphylococci (CNS).
In the Bone Marrow Transplantation (BMT) Unit of the Royal Hospital for Sick Children in Bristol, vancomycin has been used for the treatment of line-associated infections with an acceptable success rate as previously reported (Weightman, Speller & Darbyshire, 1985) . In 1992 teicoplanin was adopted as an alternative to vancomycin because of the potential advantages of ease of administration and reduced nephrotoxicity (Campoli-Richards, Brogden & Faulds, 1990) . However an audit of infectious complications on the BMT unit over a 6 month period in 1994 revealed poor treatment efficacy for CNS infections in patients with CVLs. Teicoplanin therapy was associated with preservation of the central line in only one of the six episodes. Three
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of four patients who had repeat blood cultures collected while receiving teicoplanin had persistently positive cultures (two on more than one occasion). These results then led us to review the glycopeptide susceptibility of isolates and clinical outcome associated with treatment of line-associated infections over a five year period (1990) (1991) (1992) (1993) (1994) (1995) .
Patients and methods
We identified our study population using the microbiology computer records and hospital notes. All blood cultures from which CNS were isolated from both aerobic and anaerobic bottles were identified for the period May 1990 to May 1995 from the BMT Unit, and all oncology wards in the United Bristol Healthcare Trust (UBHT). Only isolates from patients known to have a CVL in situ and who were treated with a glycopeptide were included in further studies.
All blood culture isolates are routinely stored at -70°C in glycerol broth. Study isolates were identified using the API Staph system (Bio Merieux 2050) and tested for antibiotic susceptibility. Antibiotic susceptibility was determined using the Stokes method (Holt & Brown, 1989) of susceptibility testing with a 30/ig disc. We also determined the minimum inhibitory concentration (MIC) of teicoplanin and vancomycin using a plate incorporation method (inoculum 10 3 -10*cfu/spot) (Holt & Brown, 1989) . As glycopeptides have a time dependent action (O'Hare & Reynolds, 1992) we also studied the survival of isolates following exposure to these glycopeptides over a period of time. This percentage survival was determined after exposure of isolates at a concentration of 10 6 cfu/mL to teicoplanin or vancomycin 100 mg/L for 1 h at 37°C in nutrient broth. The bacterial inoculum was prepared from 18 h nutrient broth cultures and the viable counts determined using a modification of the method of Miles & Misra (1938) . Statistical analysis was performed on these results using the Student f-test.
Assessment of clinical outcome was restricted to the BMT patients. The majority of these patients wre undergoing treatment for haematological malignancy and include both adults and children. Patients were treated with vancomycin 500 mg (lOmg/kg children) 6-hourly until 1992 or teicoplanin 400 mg (lOmg/kg children) 12-hourly for three doses and then 24-hourly after this date. The BMT unit expanded after 1992 so that more of those included in the study population received teicoplanin than vancomycin. We assessed clinical outcome by looking at fever defervescence, change of antibiotics, repeat blood cultures and CVL preservation (Table I) .
Results
From the microbiology computer records and hospital notes 135 isolates were identified that fulfilled the selection criteria. Ninety-one strains of Staphylococcus epidermidis and fifteen Staphylococcus haemolyticus were investigated by MIC (mg/L) and survival in the presence of high concentrations of glycopeptide antibiotic. The mean MIC of teicoplanin for S. epidermidis isolates was 2.2 mg/L (range 0.25-8) and 2.0 mg/L (range 1-4) for vancomycin. The 1 h survival showed teicoplanin to be more active than vancomycin against S. epidermidis: 38.7% (range 0.98-113.4%) vs 65.9% (range 5-125%); P = 0.01. The mean MIC values for S. haemolyticus were higher for teicoplanin then vancomycin; 3.6 mg/L (range 2-8) and 2.1 mg/L (range 1-4) respectively. S. haemolyticus showed higher survival with teicoplanin compared with In the review of clinical outcome of 48 episodes, 38 were treated with teicoplanin, and only 50% of these had a satisfactory clinical outcome with resolution of fever without antibiotic change or removal of CVL (Table 1 ). All the initial isolates from these episodes had low MIC values (range 0.5-4; mean 2.44 mg/mL) and were sensitive to teicoplanin on disc testing.
Further investigations were performed on eight episodes, where repeat blood cultures collected during teicoplanin treatment were positive. These isolates were compared to the initial isolates and all showed higher percentage survival with increasing duration of treatment (Table II) .
Discussion
Despite evidence in the literature of good efficacy with teicoplanin in line associated infections (Chabonneau & Gerraud, 1988; Chow et al., 1993) , this 5 year review shows comparatively poor efficacy. The percentage survival results suggest this is not due to poor sensitivity. We would suggest that because glycopeptides have a time dependent action a brief period of exposure to teicoplanin once a day is unlikely to be as effective in the eradication of line-associated bacteria as the more prolonged period of exposure resulting from use of an infusion and this may account for our poor results. Previous comparative studies have not taken account of the duration of antibiotic exposure in the interpretation of results following differing modes of administration of teicoplanin or vancomycin. We have shown high levels of survival of coagulase-negative staphylococci following exposure to teicoplanin or vancomycin for an hour. Biofilm or clot associated bacteria in vivo may be even more resistant to a brief period of antibiotic exposure (Kropec et al., 1993) .
Emergence of clones with increasing resistance to teicoplanin as seen in Table II has previously been observed (Chomaret, Esponouse & Flandrois, 1991) . There has been criticism of Chomaret's work because of the lower dose used and it may be suggested that by using teicoplanin by bolus in line-associated infections we have also, by giving inadequate exposure, predisposed to this emergence. We therefore recommend the use of teicoplanin by infusion rather than bolus administration for treatment of line associated infections and that the mode of administration should be taken into account in both the design and interpretation of studies comparing the efficacy of glycopeptide antibiotics.
